CompletedPhase 1 / PHASE2

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

Lead sponsor

PRAECIS Pharmaceuticals Inc.

Asset

PPI-1019 (APAN)

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 12-26•Study partner/caregiver required

Primary endpoint

•Safety

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID1019-04-01

NCT IDNCT00100334

Timeline

Milestones

Study start2004-12 (month precision)

Study first posted2004-12-30estimated

Study completion2005-08 (month precision)

Last update posted2006-09-19estimated

Assets

Drug assets

PPI-1019 (APAN)

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subject has the ability to understand the requirements of the study, provide written informed consent, and abide by the requirements of the study. In addition, a member of the subject's family or a legally authorized representative must consent to the subject's participation in the study.

•Subject has a caregiver willing to assist the subject's involvement in the study.

•Subject is a male or female between the ages of 50 and 80 with a body mass index (BMI) below 31. Females must be post-menopausal at least 1 year or surgically sterilized.

•Subject must have a cognitive deficit present for at least 1 year and meet DSM -IV criteria for Alzheimer's disease and meet National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for the presence of probable Alzheimer's disease.

•Subject's severity of Alzheimer's disease must be mild-moderate, documented with a Mini Mental State Exam (MMSE) score of 12-26.

•Subject has a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within the prior 12 months which is compatible with a diagnosis of probable AD.

•If a subject is being treated for Alzheimer's disease, it must be with a single cholinesterase inhibitor (donepezil, rivastigmine, or galantamine), with or without memantine, and with a dose which has been stable for at least 3 months prior to dosing.

•Subject performance status is ≤ 3 on items 1 through 5 and ≤ 2 on item 6 from the Degree of Disability Section of the "Rapid Disability Scale-2"

•Subject agrees not to donate blood or blood products while participating in this study and for at least 60 days after discontinuing from the study

Exclusion criteria

•Subject has participated in a clinical trial of another investigational drug or device, or has taken any experimental drug within 30 days prior to admission to the Phase 1 unit. (Subjects previously enrolled in 1019-03-01 may be enrolled in 1019-04-01, only after a wash-out period of 45 days.)

•Subject has a history compatible with vascular dementia as evidenced by a score of 5 or greater on the modified Hachinski Ischemia Scale.

•Subject has evidence of clinically significant unstable cardiovascular, renal, hepatic, gastrointestinal, neurological, or metabolic disease within the past 6 months (as determined by medical history, ECG results, chest x-ray, or physical examination).

•Subject performance status is > 3 on items 1 through 5 and > 2 on item 6 from the Degree of Disability Section of the "Rapid Disability Scale-2."

•Subject has diabetes that requires oral antidiabetic therapy or insulin.

•Subject has a systolic blood pressure (sitting) of greater than 160 mmHg, a diastolic (sitting) greater than 95 mmHg, a decrease in systolic blood pressure of more than 30 mmHg upon standing for 2 minutes from a sitting or supine position, a pulse (sitting or supine) less than 50 or greater than 85.

•Subject has any visual, hearing, or communication disabilities impairing his/her ability to participate in the study.

•Subject is being treated with anticholinergics and/or clinically relevant cytochrome P450 3A4 inducers/inhibitors. The use of other concomitant medications for stable medical conditions is acceptable provided drug and dosage are stable for at least 4 weeks prior to dosing.

•Subject is currently taking herbal supplements which interfere with drug metabolism, e.g. St. John's wort, ginkgo biloba.

•Subject has tested positive for drugs of abuse (amphetamines, barbiturates, cocaine, phencyclidine, or cannabinoids) on screening or Day -1

•Subject has a current or past medical history of alcohol abuse.

•Subject has any elevations (> 1.2 x ULN) on screening or Day -1 for ALT, AST, bilirubin, creatinine, blood urea nitrogen, or alkaline phosphatase.

•Subject has any other screening or Day -1 laboratory values outside the normal ranges that are deemed clinically significant by the investigator.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Safety will be assessed through the occurrence of clinical adverse events and the occurrence of clinically significant changes from baseline.

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.